TY  - JOUR
AU  - Lara, Pedro C
AU  - Rodriguez-Melcon, Juan I
AU  - Palacios-Eito, Amalia
AU  - Lozano, Antonio
AU  - Hervas-Moron, Asuncion
AU  - Villafranca, Elena
AU  - Gomez-Iturriaga, Alfonso
AU  - Sancho, Gemma
AU  - Maldonado, Xavier
PY  - 2022
DO  - 10.3389/fonc.2022.891886
SN  - 2234-943X
UR  - http://hdl.handle.net/10668/20683
T2  - Frontiers in oncology
AB  - Intermediate-risk prostate cancer (PCa) is usually treated by a combination of external beam radiation therapy (EBRT) and a short course of androgen deprivation therapy (ADT). ADT is associated with multiple side effects, including weight gain, loss...
LA  - en
PB  - Frontiers Research Foundation
KW  - Enzalutamide monotherapy
KW  - Hypofractionated
KW  - Intermediate risk
KW  - Prostate cancer
KW  - Radiotherapy
TI  - Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer.
TY  - research article
VL  - 12
ER  -